Song Haimeng, Du Xinyue, Zhang Yuanyuan, Liu Wei, Luo Yi, Liu Yuxin, Xue Yongjia, Xu Mingyang, Lu Jizhen, Jia Wenwen, Du Yanan, Cao Lining, Lu Jianfeng, Zhang Wencheng, He Zhiying
Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200123, PR China; Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, 200335, PR China; Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai, 200120, PR China.
Beijing CytoNiche Biotechnology Co. Ltd., Beijing, 100195, PR China.
Biomaterials. 2025 Oct;321:123324. doi: 10.1016/j.biomaterials.2025.123324. Epub 2025 Apr 9.
The clinical application of human umbilical cord mesenchymal stem cells (hUCMSCs) in the treatment of liver failure faces challenges due to cell quality, short engraftment time, and limited efficacy. Here, gelatin microcryogel (GM) microcarriers with pore sizes ranging from 15 to 36 μm were tuned from mixed gelatin and glutaraldehyde to develop a 3D culture system of hUCMSCs with improved therapeutic effects. Bulk RNA sequencing and in vitro assays showed that 3D-hUCMSCs exhibited significant improvement in signaling pathways related to paracrine secretion and anti-inflammation. These 3D-hUCMSCs superior compared to 2D-hUCMSCs not only in terms of paracrine secretion, protection from oxidation, and resistance to mechanical force damage, but also had better liver function improvement effect than 2D-hUCMSCs when they were transplanted as single cells into liver injury mice. Furthermore, a gelatin sponge patch grafting (GSPG) strategy was developed to enable the direct engraftment of 3D-hUCMSCs within the GM microcarriers. The results showed that overall engraftment in the host liver was significantly improved, and the life span of transplanted hosts was extended. Our study provided a practical strategy to achieve high engraftment and long retraining time of 3D-hUCMSCs in rescuing acute liver failure with gelatin matrixes.
由于细胞质量、植入时间短和疗效有限,人脐带间充质干细胞(hUCMSCs)在治疗肝衰竭方面的临床应用面临挑战。在此,通过将混合明胶和戊二醛调整为孔径范围为15至36μm的明胶微晶凝胶(GM)微载体,开发了一种具有改善治疗效果的hUCMSCs三维培养系统。大量RNA测序和体外试验表明,三维培养的hUCMSCs在与旁分泌和抗炎相关的信号通路方面有显著改善。这些三维培养的hUCMSCs不仅在旁分泌、抗氧化和抗机械力损伤方面优于二维培养的hUCMSCs,而且当它们作为单细胞移植到肝损伤小鼠体内时,在改善肝功能方面也比二维培养的hUCMSCs更好。此外,还开发了一种明胶海绵贴片移植(GSPG)策略,以使三维培养的hUCMSCs能够直接植入GM微载体内。结果表明,宿主肝脏中的整体植入率显著提高,移植宿主的寿命延长。我们的研究提供了一种实用策略,可通过明胶基质实现三维培养的hUCMSCs在抢救急性肝衰竭中的高植入率和长留存时间。